Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world

[1]  T. Sugihara,et al.  A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. , 2022, Future oncology.

[2]  E. Winer,et al.  Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. , 2022, The New England journal of medicine.

[3]  E. Rasmussen,et al.  Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2− metastatic breast cancer , 2021, Current medical research and opinion.

[4]  A. Niemierko,et al.  Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  K. Saverno,et al.  Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib , 2021, Drugs - Real World Outcomes.

[6]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[7]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Baxi,et al.  Abstract P2-08-12: Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2- metastatic breast cancer , 2020 .

[9]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[10]  L. Chow,et al.  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. , 2019, The New England journal of medicine.

[11]  J. Abraham,et al.  Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR+) metastatic breast cancer. , 2019, Journal of Clinical Oncology.

[12]  A. Niemierko,et al.  A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). , 2019, Journal of Clinical Oncology.

[13]  D. Boulware,et al.  Efficacy of abemaciclib (abema) after palbociclib (palbo) in patients (pts) with metastatic breast cancer (MBC). , 2019, Journal of Clinical Oncology.

[14]  M. Cobleigh,et al.  Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib. , 2019, Journal of Clinical Oncology.

[15]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[16]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[20]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[21]  C. Orlandini,et al.  Survival of metastatic breast carcinoma patients over a 20‐year period , 2005, Cancer.

[22]  OUP accepted manuscript , 2022, The Oncologist.

[23]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2022 , 2022 .